The DMPK team uses state of the art tools to support the selection of compounds with appropriate absorption, distribution, metabolism, and excretion properties for further development as drug candidates. An extensive range of in vitro and in vivo studies in preclinical species and in vitro studies in human preparations are available to fully profile compound candidates. Major attention is given to eliminate from further development compounds that are potentially toxic.

  • State of the art mass spectrometric equipment - LC-MS/MS including Sciex API 4000 & API 5000, TSQ-AM, UPLC-QTOF
  • Quantitative and qualitative analysis of small molecules, peptides and proteins
  • Specialized in Peptide and protein quantification in biological fluids
  • Chemical stability, solubility, log D, pKa, physicochemical properties



  • PK in all preclinical species
    • Automated blood sampling
    • Specialized in peptide and protein PK
  • Mechanistic PK Studies
    • Oral absorption and first pass extraction
    • Involvement of drug transporters in clearance and
      absorption mechanisms
  • Mass balance
  • Automated metabolic stability screening
  • Cytochrome P450 Induction and inhibition
  • Cell permeability and transport
  • Metabolic reaction phenotyping
  • Metabolite identification
  • Plasma protein binding, blood/plasma partition
  • Formulation support
  • Prediction of human PK